DK

Zealand Pharma increases its share capital as a consequence of exercise of employee warrants

Retrieved on: 
Friday, November 20, 2020

1.500 warrants er udnyttet den 13. september 2019, 55.300 warrants er udnyttet den 22. november 2019, 14.625 warrants er udnyttet den 13. december 2019, 4.325 warrants er udnyttet den 20. marts 2020, 6.250 warrants er udnyttet den 15. april 2020, 52.750 warrants er udnyttet den 26. maj 2020, 27.000 warrants er udnyttet den 12. juni 2020, 14.250 warrants er udnyttet den 21. august 2020, 10.875 warrants er udnyttet den 11. september 2020, og 4.500 warrants er udnyttet den 20. november 2020.

Key Points: 
  • 1.500 warrants er udnyttet den 13. september 2019, 55.300 warrants er udnyttet den 22. november 2019, 14.625 warrants er udnyttet den 13. december 2019, 4.325 warrants er udnyttet den 20. marts 2020, 6.250 warrants er udnyttet den 15. april 2020, 52.750 warrants er udnyttet den 26. maj 2020, 27.000 warrants er udnyttet den 12. juni 2020, 14.250 warrants er udnyttet den 21. august 2020, 10.875 warrants er udnyttet den 11. september 2020, og 4.500 warrants er udnyttet den 20. november 2020.
  • Som flge af dels udnyttelse, dels bortfald af warrants, er det udestende antal warrants, der kan udnyttes, reduceret til 90.125 warrants.
  • As a result of exercise/lapse of warrants, the number of warrants available for exercise has been reduced to 90,125 warrants.
  • 17.263 warrants er udnyttet den 15. april 2020, 38.121 warrants er udnyttet den 26. maj 2020, 14.495 warrants er udnyttet den 12. juni 2020, 8.050 er udnyttet den 21. august 2020, 2.976 warrants er udnyttet den 11. september 2020, og 11.495 warrants er udnyttet den 20. november 2020.

Zealand Pharma:

Retrieved on: 
Wednesday, November 11, 2020
Clinical medicine, Health sciences, Pharmacology, Zealand Pharma, Peptide hormones, Recombinant proteins, Insulin, Bolus

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines.

Key Points: 
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines.
  • More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market.
  • Zealand markets V-Go, an all-in-one basal-bolus insulin delivery option for people with diabetes.
  • Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA).

Nine-month interim report (Q3) 2020

Retrieved on: 
Wednesday, November 11, 2020

This result is achieved despite the continuing negative impact of COVID-19 on its legacy business, predominantly in the USA.

Key Points: 
  • This result is achieved despite the continuing negative impact of COVID-19 on its legacy business, predominantly in the USA.
  • Total revenue was up 7% organically in local currencies at DKK 772 million (739).
  • Sales in the USA are particularly impacted, and ALK estimates that the 2020 full-year total value of missed US sales will be more than DKK 100 million.
  • The conference call will also be webcast live on our website, where the related presentation will be made available shortly before the call begins.

Saniona to Participate in Stifel and Jefferies Virtual Investor Conferences in November

Retrieved on: 
Tuesday, November 10, 2020
Prader, Obesity, Branches of biology, Health

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that Rami Levin, President and Chief Executive Officer of Saniona, will participate in two upcoming virtual investor conferences: the Stifel 2020 Virtual Healthcare Conference and the Jefferies 2020 Virtual London Healthcare Conference.

Key Points: 
  • Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that Rami Levin, President and Chief Executive Officer of Saniona, will participate in two upcoming virtual investor conferences: the Stifel 2020 Virtual Healthcare Conference and the Jefferies 2020 Virtual London Healthcare Conference.
  • Subsequently, the event will be archived for approximately 90 days on the Saniona website in the Company Presentations section: https://saniona.com/investors/company-presentations/ .
  • Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system.
  • Saniona intends to develop and commercialize treatments for rare disease indications such as hypothalamic obesity and Prader-Willi syndrome on its own.

Orphazyme submits European Marketing Authorisation Application for arimoclomol for treatment of Niemann-Pick disease Type C

Retrieved on: 
Monday, November 9, 2020
Rare diseases, Branches of biology, Lipid storage disorders, Neurological disorders, Organ systems, Niemann–Pick disease, type C, Niemann–Pick disease, Inclusion body myositis, Niemann, Arimoclomol, Gaucher's disease, Amyotrophic lateral sclerosis

Orphazyme is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases.

Key Points: 
  • Orphazyme is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases.
  • Arimoclomol, the companys lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), sporadic Inclusion Body Myositis (sIBM) and Gaucher disease.
  • In addition, arimoclomol has received breakthrough therapy designation (BTD) and rare-pediatric disease designation (RPDD) from the FDA for NPC.
  • Niemann-Pick disease Type C (NPC) is a rare, genetic, progressively debilitating, and often fatal neurovisceral disease.

Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Retrieved on: 
Thursday, November 5, 2020
Non-Hodgkin lymphoma, Lymphoma, Medical specialties, Clinical medicine, Medicine, Diffuse large B-cell lymphoma, Genmab, Large-cell lymphoma, Loncastuximab tesirine, Primary testicular diffuse large B-cell lymphoma

Copenhagen, Denmark; November 5, 2020 Genmab A/S (Nasdaq: GMAB) announced today that it will initiate a Phase 3 study of epcoritamab in diffuse large B-cell lymphoma (DLBCL).

Key Points: 
  • Copenhagen, Denmark; November 5, 2020 Genmab A/S (Nasdaq: GMAB) announced today that it will initiate a Phase 3 study of epcoritamab in diffuse large B-cell lymphoma (DLBCL).
  • The Phase 3, open-label, randomized study (GCT3013-05) will include approximately 480 patients with relapsed or refractory DLBCL who failed or are ineligible for autologous stem cell transplant (ASCT).
  • Genmabs DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells.
  • Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from the International SCHOLAR-1 Study.

Zealand Pharma hosts conference call on November 12 at 4 pm CET (10am ET) to present third quarter results for 2020

Retrieved on: 
Thursday, November 5, 2020
Zealand Pharma

20045078), announced that it will host a conference call on November 12, 2020 at 4 pm CET (10 am ET) following the announcement of results for the third quarter of 2020.

Key Points: 
  • 20045078), announced that it will host a conference call on November 12, 2020 at 4 pm CET (10 am ET) following the announcement of results for the third quarter of 2020.
  • Due to increased demand of conference call services, it could take longer to be connected to the call.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines.
  • More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market.

ALK updates its full-year financial outlook

Retrieved on: 
Thursday, November 5, 2020
ALK, Anaplastic lymphoma kinase, Nasdaq Nordic, Nasdaq Copenhagen, Economy of Europe, ALK-Abelló, Companies, Protein kinase inhibitors

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its preliminary results for Q3 is showing a 7% organic revenue growth, fuelled by a 52% increase in tablet sales.

Key Points: 
  • ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its preliminary results for Q3 is showing a 7% organic revenue growth, fuelled by a 52% increase in tablet sales.
  • Therefore, the company is upgrading its earnings and cash flow outlook to DKK 350-400 million and approximately DKK 0, respectively, while narrowing its revenue growth outlook to around 8% organic growth.
  • ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma.
  • Headquartered in Hrsholm, Denmark, ALK employs around 2,400 people worldwide and is listed on Nasdaq Copenhagen.

Genmab Announces Financial Results for the First Nine Months of 2020

Retrieved on: 
Wednesday, November 4, 2020
Genmab, Industries

Revenue was DKK 8,067 million in the first nine months of 2020 compared to DKK 2,405 million in the first nine months of 2019.

Key Points: 
  • Revenue was DKK 8,067 million in the first nine months of 2020 compared to DKK 2,405 million in the first nine months of 2019.
  • Operating expenses were DKK 2,641 million in the first nine months of 2020 compared to DKK 1,943 million in the first nine months of 2019.
  • Operating income was DKK 5,426 million in the first nine months of 2020 compared to DKK 462 million in the first nine months of 2019.
  • Genmab is maintaining its 2020 financial guidance published on August 20, 2020.